China Structural Ventricular Arrhythmias Registry, a Multicenter, Observational and Prospective Study

What this Trial Is About

Researchers are conducting a prospective, observational study involving multiple centers in China to better understand malignant structural ventricular arrhythmias. The study aims to build a risk stratification model to identify risk factors and develop more efficient and cost-effective strategies for early prevention and treatment. This research is part of a larger national effort to clarify the prevalence and risk factors of this condition, which currently relies heavily on implantable devices and medication. The study will enroll 2000 participants diagnosed with ventricular arrhythmias caused by structural heart diseases such as ischemic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, and hypertrophic cardiomyopathy. At enrollment, demographic information, medical history, clinical features, lab tests, imaging, medications, procedures, and in-hospital outcomes will be collected from medical records. Blood samples will also be taken to detect biological markers like genes and inflammatory factors. Participants will be followed up every six months to monitor arrhythmia status, medication use, and clinical events. Participants will undergo interviews and provide consent at the start of the study. During follow-up visits every six months, researchers will assess episodes of arrhythmia, sustained tachycardia or ventricular fibrillation, sudden cardiac death, and overall mortality over a five-year period. The study will gather comprehensive clinical and biological data to help improve risk prediction and management of ventricular arrhythmias. The total duration of participant involvement is expected to be five years, with continuous monitoring of health outcomes and events.

China Structural Ventricular Arrhythmias Registry